Cargando…
Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis
Oral submucous fibrosis (OSMF) is considered a premalignant condition characterized by aggressive fibrosis of the submucosal tissues of the oral cavity reflecting its malignant transformation potential. Activation of transforming growth factor beta (TGF-β) signaling has been reported to lead increas...
Autor principal: | Boreak, Nezar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035005/ https://www.ncbi.nlm.nih.gov/pubmed/33869629 http://dx.doi.org/10.1155/2021/6631848 |
Ejemplares similares
-
Oral Submucous Fibrosis: Etiological Mechanism, Malignant Transformation, Therapeutic Approaches and Targets
por: Qin, Xiaofeng, et al.
Publicado: (2023) -
Pathogenesis and therapeutic intervention of oral submucous fibrosis
por: Yoithapprabhunath, Thukanaykanpalayam Ragunathan, et al.
Publicado: (2013) -
Interplay of Transforming Growth Factor-Beta 1 and 3 in the Pathogenesis of Oral Submucous Fibrosis and Its Malignant Transformation: An Immunohistochemical Study
por: Bansal, Shivani, et al.
Publicado: (2023) -
Comparison of Immunohistochemical Markers in Oral Submucous Fibrosis and Oral Submucous Fibrosis Transformed to Oral Squamous Cell Carcinoma—A Systematic Review and Meta-Analysis
por: Mohapatra, Diksha, et al.
Publicado: (2023) -
Oral submucous fibrosis: an update
por: Wollina, Uwe, et al.
Publicado: (2015)